An observational study in Ultra-trail Participation, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-02.
Sponsored by University Hospital, Clermont-Ferrand · Observational
To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
During physical exercise, increased sympathetic nervous system activity redistributes blood flow from splanchnic organs to working muscles. With prolonged duration and / or intensity, the splanchnic blood flow can be reduced by 80% or more. A severely reduced of splanchnic blood flow can frequently cause gastrointestinal ischemia. This ischemia associated with reduced vagal activity probably results in changes in motility and absorption.
High symptoms are reported in 40% of runners with reflux and heartburn in 15-20% of runners. The low symptoms have an incidence of about 70% in the long runs type ultra-trail.
Biological markers such as I-FABP have been shown to be useful in the diagnosis of mesenteric ischemia.
participants or populations are selected based on predefined criteria
Exclusion Criteria:
To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
Biological: Blood analysis
Blood test of biological markers of mesenteric ischemia
Assess biological markers of mesenteric ischemia (IFABP)
during ultratrail.
Time frame: at day 1
Relationship between digestive symptoms and biological markers (IFABP).
Time frame: at day 1
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand